Phase I Study of Pazopanib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumors

PURPOSE. To evaluate the maximum tolerated regimen (MTR), dose-limiting toxicities, and pharmacokinetics of pazopanib, an oral small-molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit, in combination with paclitaxel....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Tan, Antoinette R., Dowlati, Afshin, Jones, Suzanne F., Infante, Jeffrey R., Nishioka, Jennifer, Fang, Lei, Hodge, Jeffrey P., Gainer, Shelby D., Arumugham, Thangam, Suttle, A. Benjamin, Dar, Mohammed M., Lager, Joanne J., Burris, Howard A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: AlphaMed Press 2010
Schlagworte:
Clinical Pharmacology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227920/
https://ncbi.nlm.nih.gov/pubmed/21147873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0095
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge